Display options
Cite
Canchola AJ, Anton-Culver H, Bernstein L, et al. Body size and the risk of postmenopausal breast cancer subtypes in the California Teachers Study cohort. Cancer Causes Control. 2012;doi: 10.1007/s10552-012-9897-x.
Canchola, A. J., Anton-Culver, H., Bernstein, L., Clarke, C. A., Henderson, K., Ma, H., Ursin, G., & Horn-Ross, P. L. (2012). Body size and the risk of postmenopausal breast cancer subtypes in the California Teachers Study cohort. Cancer causes & control : CCC, . https://doi.org/10.1007/s10552-012-9897-x
Canchola, Alison J, et al. "Body size and the risk of postmenopausal breast cancer subtypes in the California Teachers Study cohort." Cancer causes & control : CCC vol. (2012). doi: https://doi.org/10.1007/s10552-012-9897-x
Canchola AJ, Anton-Culver H, Bernstein L, Clarke CA, Henderson K, Ma H, Ursin G, Horn-Ross PL. Body size and the risk of postmenopausal breast cancer subtypes in the California Teachers Study cohort. Cancer Causes Control. 2012 Jan 28; doi: 10.1007/s10552-012-9897-x. Epub 2012 Jan 28. PMID: 22286371; PMCID: PMC3366039.
Copy Download .nbib Format: NLM
Share it on

Cancer Causes Control. 2012 Jan 28; doi: 10.1007/s10552-012-9897-x. Epub 2012 Jan 28.

Body size and the risk of postmenopausal breast cancer subtypes in the California Teachers Study cohort.

Cancer causes & control : CCC

Alison J Canchola, Hoda Anton-Culver, Leslie Bernstein, Christina A Clarke, Katherine Henderson, Huiyan Ma, Giske Ursin, Pamela L Horn-Ross

Affiliations

  1. Cancer Prevention Institute of California, 2201 Walnut Avenue, Suite 300, Fremont, CA, 94538, USA, [email protected].

PMID: 22286371 PMCID: PMC3366039 DOI: 10.1007/s10552-012-9897-x

Abstract

PURPOSE: To evaluate how the association between body size and breast cancer risk varies by tumor receptor subtype, host factors, and other exposures among women in the California Teachers Study cohort. METHODS: Among 52,642 postmenopausal women, 2,321 developed invasive breast cancer with known estrogen- and progesterone-receptor status (1,652 ER+PR+, 338 ER+PR-, and 312 ER-PR-) between 1995 and 2007. In a subset of 35,529 with waist circumference data, 1,377 developed invasive breast cancer with known ERPR status (991 ER+PR+, 208 ER+PR-, 169 ER-PR-) between 1997 and 2007. Multivariate Cox regression was performed to estimate relative risks (RR) and 95% confidence intervals (CI). RESULTS: Obesity, adult weight gain of ≥40 pounds, greater abdominal adiposity, and greater height increased the risk of ER+PR+ breast cancer. The increased risk associated with postmenopausal obesity was limited to those who did not use hormone therapy (HT) at cohort entry (RR = 1.37; 95% CI, 1.05-1.78 for BMI ≥ 30 vs. < 25 kg/m(2); p-interaction = 0.14) and those who were not overweight or obese at age 18 (p-interaction = 0.06). The increased risk associated with greater abdominal adiposity was limited to those who were not also overweight or obese (p-interaction = 0.01). Neither obesity, abdominal adiposity, nor height was associated with the risk of ER-PR- tumors. CONCLUSIONS: The effects of body size on postmenopausal breast cancer risk differed by hormone receptor subtype, and among women with ER+PR+ tumors, by HT use and early adult body size.

References

  1. Cancer Epidemiol Biomarkers Prev. 2000 Jul;9(7):681-7 - PubMed
  2. Int J Obes Relat Metab Disord. 1998 Aug;22(8):719-27 - PubMed
  3. Curr Diab Rep. 2011 Jun;11(3):179-84 - PubMed
  4. Am J Epidemiol. 2000 Apr 1;151(7):703-14 - PubMed
  5. Am J Epidemiol. 1999 Dec 15;150(12):1316-24 - PubMed
  6. Exp Clin Endocrinol Diabetes. 2010 Nov;118(10):713-8 - PubMed
  7. Cancer Causes Control. 2000 Jul;11(6):533-42 - PubMed
  8. Am J Epidemiol. 1988 Oct;128(4):740-8 - PubMed
  9. Breast J. 2010 May-Jun;16(3):323-4 - PubMed
  10. Cancer Epidemiol Biomarkers Prev. 2009 Aug;18(8):2214-20 - PubMed
  11. Breast Cancer Res. 2010;12(1):R4 - PubMed
  12. Cancer Causes Control. 2002 Oct;13(8):741-51 - PubMed
  13. Cancer Causes Control. 2002 Sep;13(7):625-35 - PubMed
  14. Breast Cancer Res Treat. 2005 Mar;90(2):127-37 - PubMed
  15. J Natl Cancer Inst. 1990 Feb 21;82(4):286-90 - PubMed
  16. Lancet Oncol. 2011 Aug;12(8):785-94 - PubMed
  17. Cancer Epidemiol Biomarkers Prev. 2004 Feb;13(2):220-4 - PubMed
  18. BMC Med Genomics. 2010 Dec 23;3:61 - PubMed
  19. Cancer Epidemiol Biomarkers Prev. 2007 Sep;16(9):1795-802 - PubMed
  20. Am J Epidemiol. 2011 Sep 15;174(6):661-71 - PubMed
  21. Am J Epidemiol. 2009 May 15;169(10):1251-9 - PubMed
  22. PLoS One. 2011 Mar 23;6(3):e17154 - PubMed
  23. Cancer Causes Control. 2006 Jun;17(5):695-703 - PubMed
  24. J Natl Cancer Inst. 2002 Apr 17;94(8):606-16 - PubMed
  25. Arch Intern Med. 2007 Oct 22;167(19):2091-102 - PubMed
  26. Cancer Epidemiol Biomarkers Prev. 1995 Jun;4(4):319-26 - PubMed
  27. Nat Rev Cancer. 2004 Aug;4(8):579-91 - PubMed
  28. Cancer Epidemiol Biomarkers Prev. 2004 Oct;13(10):1558-68 - PubMed
  29. Cancer. 2006 Jul 1;107(1):12-21 - PubMed
  30. Int J Cancer. 2009 Feb 1;124(3):698-712 - PubMed
  31. Int J Cancer. 2006 Oct 1;119(7):1683-9 - PubMed
  32. Breast Cancer Res Treat. 2010 Oct;123(3):641-9 - PubMed
  33. Ann Epidemiol. 2002 Aug;12(6):435-4 - PubMed
  34. Am J Epidemiol. 2000 Nov 15;152(10):950-64 - PubMed
  35. Cancer Causes Control. 2008 Aug;19(6):595-603 - PubMed
  36. Cancer Epidemiol Biomarkers Prev. 2003 Oct;12(10):1053-60 - PubMed
  37. Int J Cancer. 2002 May 20;99(3):445-52 - PubMed
  38. J Natl Cancer Inst. 2011 Feb 2;103(3):250-63 - PubMed
  39. Int J Cancer. 2004 Sep 20;111(5):762-71 - PubMed
  40. Cancer Epidemiol Biomarkers Prev. 2010 Jun;19(6):1532-44 - PubMed
  41. Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2482-8 - PubMed

Publication Types

Grant support